119 related articles for article (PubMed ID: 26894302)
1. Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients.
Wolters R; Ebner F; Janni W; Novopashenny I; Wöckel A; Kreienberg R; Wischnewsky M; Schwentner L;
Arch Gynecol Obstet; 2016 Aug; 294(2):377-84. PubMed ID: 26894302
[TBL] [Abstract][Full Text] [Related]
2. Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?
Stüber T; Novopashenny I; Diessner J; Bartmann C; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Wöckel A; Wischnewsky M
Oncology; 2017; 92(6):317-324. PubMed ID: 28334705
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
4. Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.
Ebner F; Wöckel A; Janni W; Kreienberg R; Schwentner L; Wischnewsky M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1823-1831. PubMed ID: 28439713
[TBL] [Abstract][Full Text] [Related]
5. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients.
Wolters R; Wöckel A; Janni W; Novopashenny I; Ebner F; Kreienberg R; Wischnewsky M; Schwentner L;
Breast Cancer Res Treat; 2013 Dec; 142(3):579-90. PubMed ID: 24258258
[TBL] [Abstract][Full Text] [Related]
6. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Hanrahan EO; Valero V; Gonzalez-Angulo AM; Hortobagyi GN
J Clin Oncol; 2006 May; 24(13):2113-22. PubMed ID: 16648513
[TBL] [Abstract][Full Text] [Related]
7. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0).
Leitner SP; Swern AS; Weinberger D; Duncan LJ; Hutter RV
Cancer; 1995 Dec; 76(11):2266-74. PubMed ID: 8635031
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.
Houvenaeghel G; Goncalves A; Classe JM; Garbay JR; Giard S; Charytensky H; Cohen M; Belichard C; Faure C; Uzan S; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Lambaudie E; Coutant C; Dravet F; Chauvet MP; Chéreau Ewald E; Penault-Llorca F; Esterni B
Ann Oncol; 2014 Mar; 25(3):623-628. PubMed ID: 24399079
[TBL] [Abstract][Full Text] [Related]
10. Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients.
Schwentner L; Wolters R; Wischnewsky M; Kreienberg R; Wöckel A
Breast; 2012 Apr; 21(2):171-7. PubMed ID: 21945313
[TBL] [Abstract][Full Text] [Related]
11. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
12. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Study of Treatment Patterns and Natural History of Patients with T1a/b N0 Triple-Negative Breast Cancers: A Single-Institution Experience.
Liu L; Lewis N; Sun W; Whiting J; Hoover S; Costa RLB
Oncology; 2023; 101(12):765-772. PubMed ID: 37527637
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
[TBL] [Abstract][Full Text] [Related]
15. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L
PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098
[TBL] [Abstract][Full Text] [Related]
16. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
17. Can we select which patients with small breast cancers should receive adjuvant chemotherapy?
Wood WC; Anderson M; Lyles RH; Styblo TM; Murray D; Staley C; Yang L; Carlson G
Ann Surg; 2002 Jun; 235(6):859-62. PubMed ID: 12035043
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O; Coskun U; Sener N; Inanc M; Akman T; Ulas A; Yazilitas D; Bal O; Kucukoner M; Yildirim Ozdemir N; Demirci U; Gunaydin Y; Yildiz R; Karaca H; Umit Unal O; Gumus M; Benekli M; Buyukberber S
Onkologie; 2013; 36(10):554-8. PubMed ID: 24107908
[TBL] [Abstract][Full Text] [Related]
19. Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.
Herr D; Wischnewsky M; Joukhadar R; Chow O; Janni W; Leinert E; Fink V; Stüber T; Curtaz C; Kreienberg R; Blettner M; Wollschläger D; Wöckel A
PLoS One; 2019; 14(7):e0218434. PubMed ID: 31283775
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
Gori S; Clavarezza M; Siena S; Foglietta J; Tarenzi E; Giordano M; Molino A; Graiff C; Fusco V; Alabiso O; Baldini E; Gamucci T; Altavilla G; Dondi D; Venturini M
BMC Cancer; 2012 Apr; 12():158. PubMed ID: 22545982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
